Shots:
- Eureka and MSK are eligible to receive up front and ~$1B as development, regulatory and sales milestone along with royalties on net sales. Sanofi gets exclusive rights to the GPRC5D binder for non-CAR use
- Eureka discovered the GPRC5D binding domain using its E-ALPHA Abs discovery platform, under its collaboration with MSK
- Additionally, targeting GPRC5D may improve the durability of response from current therapies and improves the long-term clinical benefits for patients
Click here to read full press release/ article | Ref: Businesswire | Image: Eureka Therapeutics
The post Sanofi Signs ~$1B Agreement with Eureka & MSK for their Multiple Myeloma Candidate first appeared on PharmaShots.
